التفاصيل البيبلوغرافية
| العنوان: |
Circulating MicroRNA-122 as a Potential Biomarker for Hepatitis C Virus Induced Hepatocellular Carcinoma. |
| المؤلفون: |
Malik, Abdul, Barooah, Prajjalendra, Saikia, Snigdha, Medhi, Subhash, Kalita, Simanta, Kalita, Manash Jyoti, Das, Partha Pratim, Dutta, Kalpajit, Bharali, Pooja, Sarma, Manash Pratim, Sarma, Preeti, Bhattacharyya, Mallika, Kar, Premashis, Goswami, Bhabadev, Alkholief, Musaed, Alshamsan, Aws |
| المصدر: |
International Journal of Cancer Management; Nov2022, Vol. 15 Issue 11, p1-9, 9p |
| مصطلحات موضوعية: |
REVERSE transcriptase polymerase chain reaction, CONFIDENCE intervals, CHRONIC diseases, VIRAL load, MICRORNA, HEPATITIS C, QUANTITATIVE research, CIRRHOSIS of the liver, RESEARCH funding, DESCRIPTIVE statistics, TUMOR markers, RECEIVER operating characteristic curves, HEPATOCELLULAR carcinoma, ALANINE aminotransferase, ASPARTATE aminotransferase, DISEASE complications |
| مستخلص: |
Background: The microRNA (miRNA) mediated translational repression can cause various diseases in humans. The liver-specific miRNA (microRNA-122 (miR-122)) is primarily involved in tissue tropism during hepatitis C virus (HCV) infection which ultimately leads to hepatocellular carcinoma (HCC). Objectives: This study focuses on evaluating host serum miR-122 as a prognostic marker in HCV-induced hepatocellular carcinoma. Methods: Evaluation of miR-122 expression was carried out by quantitative real time PCR. Results: Positive expression of miR-122 was observed in patients with chronic hepatitis C (CHC) followed by HCC patients compared to healthy controls. A difference in median levels of the miR-122 expression in CHC and HCC patients (P < 0.000) was found in contrast to cirrhosis patients (P = 0.511). The serum miR-122 expression was found threefold higher in liver cirrhosis patients than chronic hepatitis. Further, the area under the receiver operating characteristic curve (AUROC) analysis of miR-122 expression profile can efficiently distinguish CHC patients (AUROC = 0.978, P = 0.000, 95% confidence interval (CI) = 0.958 to 0.998) and HCC from healthy controls (AUROC= 0.971, P = 0.000, 95% CI = 0.944 to 0.997). Moreover, receiver operating characteristic (ROC) curve analysis significantly distinguished between CHC patients from cirrhosis patients (AUROC = 0.955, P = 0.000, 95% CI = 0.925 to 0.986) but not CHC from HCC patients (AUROC = 0.584, P = 0.104, 95% CI = 0.485 to 0.684). This study revealed a substantial correlation of miR-122 with HCV viral load (r = 0.56, P = 0.000), ALT (r = 0.67, P = 0.000) and AST (r = 0.65, P = 0.000) levels. Conclusions: Serum miR-122 can potentially serve as a promising prognostic tool for HCV induced HCC. [ABSTRACT FROM AUTHOR] |
|
Copyright of International Journal of Cancer Management is the property of Medical Journals Commission of the Ministry of Health & Medical Education and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
